Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients

Transplantation

Volumn 87, Issue 3, 2009, Pages 424-435

  Fortún, Jesus ^a   Martín Dávila, Pilar ^a   Montejo, Miguel ^b   Muñoz, Patricia ^c   Cisneros, José M ^d   Ramos, Antonio ^e   Aragón, Cesar ^f   Blanes, Marino ^g   San Juan, Rafael ^h   Gavaldá, Joan ⁱ   Llinares, Pedro ^j  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

more..

Author keywords

Caspofungin; Liver transplantation; Prophylaxis

Indexed keywords

AZATHIOPRINE; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR MONOCLONAL ANTIBODY ANTAGONIST; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; TACROLIMUS; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; FLICE INHIBITORY PROTEIN;

ARTICLE; CANDIDA ALBICANS; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOR; MULTICENTER STUDY; MYCOSIS; PATIENT SAFETY; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; SURGICAL INFECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; DRUG ADMINISTRATION; METHODOLOGY; MICROBIOLOGY; POSTOPERATIVE COMPLICATION;

ADULT; ANTIFUNGAL AGENTS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; LIVER TRANSPLANTATION; MYCOSES; POSTOPERATIVE COMPLICATIONS; RESEARCH DESIGN;

EID: 61849170634     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181932e76     Document Type: Article

References (38)

1. Rabkin JM, Oroloff SL, Corless CL,et al. Associationoffungal infection and increased mortality in liver transplant recipients. Am J Surg 2000; 179: 426.
2. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44.
3. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999; 78: 123.
4. Kusne S, Torre-Cisneros J, Mañez R, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166: 1379.
5. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990. Transplantation 1997; 64: 716.
6. GavaldaJ, LenO,San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis 2005; 41: 52.
7. Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14: 375.
8. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644.
9. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62: 926.
10. Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8: 1065.
11. Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: A multi-center prospective observational study. Am J Transplant 2006; 6: 386.
12. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: Prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023.
13. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46.
14. CrucianiM,MengoliC,MalenaM,et al. Antifungal prophylaxisinliver transplant patients: A systematic review and meta-analysis. Liver Transpl 2006; 12: 850.
15. Playford EG, Webster AC, Sorrell TC, et al. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006; 25: 549.
16. Playford EG, Webster AC, Sorell TC, et al. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004; 3: CD004291.
17. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: Considerations for clinical trial design. Clin Infect Dis 2004; 39(suppl 4): S200.
18. Singh N, Paterson DL, Gayowski T, et al. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71: 910.
19. Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infectionsin liver transplant recipients: The roleofprophylaxis with lipid formulationsof amphotericinBinhigh-risk patients. J Antimicrob Chemother 2003; 52: 813.
20. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143.
21. Ifran A, Kaptan K, Beyan C. Efficacy of caspofungin in prophylaxis and treatment of an adult leukemic patient with invasive pulmonary aspergil-losis in allogeneic stem cell transplantation. Mycoses 2005; 48: 146.
22. Chou LS, Lewis RE, Ippoliti C, et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27: 1644.
23. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoinga bone marrowor peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331.
24. Veroux M, Macarone M, Fiamingo P, et al. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. Transplant Proc 2006; 38: 1037.
25. Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006; 34: 328.
26. Said T, Nampoory MR, Nair MP, et al. Safety of caspofungin for treating invasive nasal sinus aspergillosis in a kidney transplant recipient. Transplant Proc 2005; 37: 3038.
27. Goicoechea M, Fierer J, Johns S. Treatment of candidal cholangitis with caspofungin therapy in a patient with a liver transplant: Documentation of biliary excretion of caspofungin. Clin Infect Dis 2004; 38: 1040.
28. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006; 81: 320.
29. Petrovic J, Ngai A, Bradshaw S, et al. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc 2007; 39: 3117.
30. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7.
31. Singhal S, Ellis RW, Jones SG, et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 2000; 6: 588.
32. Castroagudin JF, Ponton C, Bustamante M, et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 2005; 37: 3965.
33. Reed A, Herndon JB, Ersoz N, et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 2007; 13: 1743.
34. Kontoyiannis DP, Lewis RE, Osherov N, et al. Combination of caspo-fungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003; 51: 313.
35. Singh N, Wagener MM, Cacciarelli TV, et al. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8: 426.
36. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: The first in a new class of antifungal agents. Drug Resist Updat 2003; 6: 197.
37. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofun-gin and cyclosporin A. Transpl Infect Dis 2004; 6: 110.
38. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13.